The other is an alternative mechanism of activating development and proliferation, which includes activation oncoproteins such as MET, HER2, BRAF or PIK3CA, cellular transformation induction including epithelial to mesenchymal transition (EMT) or transformation from NSCLC to small cell lung cancer (SCLC). This evidence concerns the gene MET and non-small cell lung carcinoma.